THE EFFECT ON BONE MASS AND BONE MARKERS OF DIFFERENT DOSES OF IBANDRONATE - A NEW BISPHOSPHONATE FOR PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-FINDING STUDY
P. Ravn et al., THE EFFECT ON BONE MASS AND BONE MARKERS OF DIFFERENT DOSES OF IBANDRONATE - A NEW BISPHOSPHONATE FOR PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-FINDING STUDY, Bone, 19(5), 1996, pp. 527-533
The present article describes the results from a phase II dose finding
study of the effect of ibandronate, a new, third generation bisphosph
onate, in postmenopausal osteoporosis, One hundred and eighty postmeno
pausal, white women, at least 10 years past a natural menopause, with
osteopenia defined as a bone mineral density (BMD) in the distal forea
rm at least 1.5 SD below the premenopausal mean, entered and 141 (78%)
completed a 12 months randomized, double-blind, placebo-controlled st
udy, The women received 0.25, 0.5, 1.0, 2.5, or 5.0 mg ibandronate dai
ly or placebo, All women received a daily calcium supplementation of 1
000 mg Ca2+, Bone mass and biochemical markers of bone turnover were m
easured every 3 months throughout the study period, The average change
s in bone mass showed positive outcome in all regions in the groups re
ceiving ibandronate 2.5 and 5.0 mg, The responses in the two groups we
re not significantly different, although there was a tendency toward a
higher response in bone mass in the group receiving ibandronate 2.5 m
g, where the increase in BMD was 4.6 +/- 3.1% (SD) in the spine (p < 0
.001), 1.3 +/- 3.0% (SD) to 3.5 +/- 5.3% (SD) in the different regions
of the proximal femur ip < 0.03 to p < 0.002), and 2.0 +/- 1.9% (SD)
in total body bone mineral content (BMC) (p < 0.001), There was no sig
nificant changes in bone mass in the group receiving calcium (placebo)
and ibandronate 0.25 mg, Dose-related responses were found in all bio
chemical markers of bone turnover, In average, serum osteocalcin decre
ased 13 +/- 14% (SD) (placebo) and 35 +/- 14%(SD) (5.0 mg), Urinary ex
cretions of breakdown products of type I collagen decreased 35 +/- 21%
(SD) (placebo) and 78 +/- 28 % (SD) (5.0 mg), p < 0.001 in all groups
, In conclusion, the results suggest that ibandronate treatment increa
ses bone mass in all skeletal regions in a dose dependent manner with
2.5 mg being the most effective dose, Ibandronate treatment reduces bo
ne turnover to premenopausal levels and is well tolerated. (C) 1996 by
Elsevier Science Inc.